ArticleBMC endocrine disorders2025
Impact of DIO2 polymorphisms on quality of life and TSH suppression therapy in patients with papillary thyroid cancer.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent Advances in the Treatment of Thyroid Pathologies with Selenium-Containing Compounds, Nanoparticles and Nanocomplexes Based on Selenium and Selenoproteins.Biological trace element research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aims to explore the impact of type 2 deiodinase (DIO2) polymorphisms on TSH suppression therapy and quality of life in patients with papillary thyroid cancer.
methodsA cohort of 200 patients with papillary thyroid cancer was recruited at Zhongshan Hospital, Xiamen University, between September 2021 and September 2022, with 88 in the lobectomy group and 74 in the total thyroidectomy plus 131I treatment group. Clinical data were collected, and quality of life was evaluated using the EQ-5D-3L scale. Genetic polymorphisms rs225014 and rs12885300 of DIO2 were analyzed from whole blood samples.
resultsIn comparison between the two surgical treatments, the total thyroidectomy plus 131I treatment group had lower scores in usual activities (P = 0.016), anxiety/ depression (P < 0.001), EQ-5D index (P < 0.001), and EQ VAS (P < 0.001) than the lobectomy group. In the lobectomy group, DIO2 rs225014 and rs12885300 polymorphisms did not significantly impact quality of life, thyroid hormone levels, or replacement therapy doses. However, in the total thyroidectomy plus 131I treatment group, patients with DIO2 rs225014 wild type (AA) exhibited higher EQ-5D index scores than those with mutant types (AG, GG) (P = 0.025). In a multiple linear regression model, using L-T4 Dose/Weight as the dependent variable, DIO2 rs225014 mutant types (AG, GG) were positively correlated with L-T4 Dose/Weight (β = 0.244, P = 0.028).
conclusionPatients in the lobectomy group exhibited higher quality of life than those in the total thyroidectomy plus 131I treatment group. In the latter, DIO2 rs225014 mutant genotypes (AG, GG) showed a modestly lower EQ-5D index score and a slight association with higher L-T4 dose/weight ratios. No significant differences were found for DIO2 rs12885300. These findings, limited by sample size and effect size, require validation in larger, multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.